Homepage Top Section1

Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101, the company’s investigational antibody-drug conjugate

Clover will use the funding to conduct the global pivotal phase 2/3 efficacy clinical trial of the protein-based S-Trimer Covid-19 vaccine candidate. It will also use the funds

Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to

The multicentre trial has been designed to assess the safety and efficacy of oral niclosamide formulation to treat patients with moderate Covid-19 disease. The study is said to

Veklury is now the first treatment to have been approved by the FDA for Covid-19. It has been approved to be used in adult as well as paediatric

Branaplam has been demonstrated to decrease levels of mutant huntingtin protein in preclinical models, said Novartis. Based on the results, Novartis aims to begin a development programme for

With a combined area of 8,700m² in the Stellar 32 campus within Geneva’s ZIPLO, the newly expanded facility will co-locate primary European operations of both companies. KBI Biopharma’s

The approval from an Indian regulator allows conducting an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in the country. According to RDIF, the multi-centre and

The human adenovirus (hAd5) vector vaccine candidate has been designed to target both the inner nucleocapsid (N) and outer spike (S) proteins, said ImmunityBio. The N-protein has been